Coherus Oncology (CHRS) Share-based Compensation Growth (1y) (2014 - 2026)
Coherus Oncology (CHRS) Share-based Compensation Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -40.86% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn | 881.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 881.48% |
| Dec 31, 2025 | 101.32% |
| Sep 30, 2025 | -99.72% |
| Jun 30, 2025 | -89.25% |
| Mar 31, 2025 | -38.32% |
| Dec 31, 2024 | -390.14% |
| Sep 30, 2024 | -31.00% |
| Jun 30, 2024 | -96.03% |
| Mar 31, 2024 | 200.76% |
| Dec 31, 2023 | 101.03% |
| Sep 30, 2023 | 92.40% |
| Jun 30, 2023 | 120.21% |
| Mar 31, 2023 | -95.07% |
| Dec 31, 2022 | -422.19% |
| Sep 30, 2022 | 2,046.47% |
| Jun 30, 2022 | 12.05% |
| Mar 31, 2022 | 232.25% |
| Dec 31, 2021 | 139.94% |
| Sep 30, 2021 | -95.92% |
| Jun 30, 2021 | -29.02% |